ISELIN, N.J., Sept. 12 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD.OB), today announced that it will host a symposium entitled "Post-Operative Adhesions in Cardiac Surgery: Challenges and Solutions" for surgeons attending next week's European Association for Cardio- Thoracic Surgery Annual Meeting in Geneva, Switzerland. The symposium will be chaired by Professor Stephen Westaby of the John Radcliffe Hospital in Oxford, United Kingdom and will include presentations by principal investigators who participated in US and European clinical trials for REPEL-CV(R) Adhesion Barrier, the company's novel bioresorbable film intended to reduce the formation of adhesions (scar tissue) in cardiac surgical procedures. Professor Westaby stated, "It is important to inform our surgeon colleagues that, with REPEL-CV, we now appear to a have way of reducing patient risks associated with the presence of adhesions during cardiac reoperations."
SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products based on its proprietary bioresorbable polymer technology.
Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain required FDA and other regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 for a description of these, as well as other, risks and uncertainties.
|SOURCE SyntheMed, Inc.|
Copyright©2007 PR Newswire.
All rights reserved